Therefore, for the first time, we synthesized a controlled release and dual-targeting system using PDA-coated MSN as the doxorubicin (DOX) carrier and conjugating NGR as the targeting ligand (MSN-DOX-PDA-NGR) to dual-target the endothelial and glioma cells. The gene discussed is RTN4R; the disease is central nervous system cancer.